Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM27KFY)

Drug Name
SB-207266A Drug Info
Synonyms
Piboserod hydrochloride; Piboserod HCl; Piboserod (hydrochloride); 178273-87-5; UNII-61Z0VMM0AJ; SB 207266A; 61Z0VMM0AJ; Piboserod hydrochloride [USAN]; SB-207266-A; Piboserod hydrochloride (USAN); N-[(1-Butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide monohydrochloride; SB 207266 hydrochloride; SB-207266A; AC1L42ON; MLS006010278; SCHEMBL2228911; CHEMBL2106927; DTXSID40170453; UABVCZHWRUGYSR-UHFFFAOYSA-N; MolPort-042-665-633; HY-15574A; AKOS030526663; API0004730; SMR004701348; FT-0724495; D05471
Indication
Disease Entry ICD 11 Status REF
Irritable bowel syndrome DD91.0 Phase 2 [1]
Cross-matching ID
PubChem CID
177335
CAS Number
CAS 178273-87-5
TTD Drug ID
DM27KFY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 4 receptor (HTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [3]
Tegaserod DM3XYD1 Irritable bowel syndrome DD91.0 Approved [4]
R0-93877 DMM4U9G Constipation DD91.1 Approved [2]
HTF 919 DM78G6F Constipation DD91.1 Approved [5]
Mosapride DM2VOQ3 N. A. N. A. Phase 4 [6]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [7]
Lintopride DMSHGWN Nausea MD90 Phase 2 [8]
TD-8954 DM3C9NV Gastrointestinal disease DE2Z Phase 2 [9]
YKP-GI DM740LV Constipation DD91.1 Phase 2 [10]
TD-5108 DM6SANW Gastroparesis DA41.00 Phase 2 [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Antagonist [2]

References

1 Clinical pipeline report, company report or official report of Department of Pharmacology University of Wisconsin School of Medicine.
2 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
3 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
4 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
5 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
6 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
7 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
8 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
9 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
10 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.